Generic Name and Formulations:
Water, hydrofluorocarbon 134a (propellant), glycerin, ethylhexyl palmitate, cetearyl alcohol, propylene glycol, dicetyl phosphate, theobroma grandiflorum seed butter, petrolatum, dimethicone, steareth-10, ceteareth-10 phosphate, tocopheryl acetate, methylparaben, disodium EDTA, propylparaben, sodium hyaluronate and sodium hydroxide; emollient foam.
Encore Dermatology, Inc.
Indications for HYLATOPIC:
Dermatitis (including radiation dermatitis). Dry skin.
Adults and Children:
Apply and massage into affected area 3 times daily or as needed. Broken skin: may be occluded.
Avoid eyes, mucous membranes, exposure to sun. Treatment may be continued during antiinfective therapy. Reevaluate if no improvement after 10–14 days. Flammable.
Radiation therapy: may dissolve fuchsin dye; do not use 4 hours prior to session.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Nicotinamide and Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML